Minerva Neurosciences (NASDAQ:NERV) focuses on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Its mission centers on addressing the unmet medical needs of patients suffering from neuropsychiatric diseases and other disorders. The company works on a variety of projects, including innovative treatments for schizophrenia, insomnia, and Parkinson’s disease, among others. Minerva aims to improve the lives of patients by pursuing the rigorous development of its therapeutic candidates, guided by scientific research and clinical studies. Through its dedicated efforts, Minerva strives to bring new, effective solutions to the healthcare market, aiding those affected by challenging CNS conditions.